Business
CAPR Deadline: Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a c...
About this update from Caprock Mining Corp
[{"type":"text","content":"CAPR Deadline: Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Losses to Contact the Firm for Information About Their Rights\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company.\n \n\n For more information, submit a\n \n form\n \n ,\n \n email\n \n attorney Phillip Kim, or give us a call at 866-767-3653.\n \n\n The Allegations: Rosen Law Firm is Investigating the Allegations that Capricor Therapeutics, Inc. (NASDAQ: CAPR) Misled Investors Regarding its Business Operations.\n \n\n According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning deramiocel, Capricor’s lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Further, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. The lawsuit alleges this caused shareholders to purchase Capricor’s securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.\n \n\n What Now: You may be eligible to participate in the class action against Capricor Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 15, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click\n \n here\n \n .\n \n\n All ...